Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Azenosertib · KP-2638

Small molecule · Inhibitor of WEE1 tyrosine kinase (WEE1) · developed by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals

Phase 3 Most advanced trial
ZNTL Developer
4 Registered trials

What is Azenosertib?

Azenosertib is an oral small-molecule inhibitor of the WEE1 tyrosine kinase, which normally phosphorylates CDK1 in the CDK1/cyclin B complex to block entry into mitosis. By inhibiting WEE1, it removes the G2 checkpoint, promoting premature mitosis and cell death in susceptible tumor cells, particularly p53-deficient or mutated cancers treated with DNA-damaging agents. It is being studied in pancreatic ductal adenocarcinoma, ovarian cancer, and acute myeloid leukemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
KP-2638, ZN-c3, Zentalis, C29H34N8O2
Drug type
Small molecule
Targets
WEE1 tyrosine kinase (WEE1)
Mechanism
Inhibitor of WEE1 tyrosine kinase (WEE1)
Pathways
G2/M checkpoint, CDK1/cyclin B mitotic entry, DNA damage response
Therapy area
Oncology
Developer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc (ZNTL)
Also in trials of
CRDF
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
9J13XU96Z1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07546500 Phase 3 Ovarian Cancer Recruiting ZNTL
NCT06015659 Phase 2 Advanced Pancreatic Adenocarcinoma Terminated ZNTL
NCT05682170 Phase 1/2 Acute Myeloid Leukemia (AML) Terminated ZNTL
NCT04005690 Early Phase 1 Locally Advanced Pancreatic Ductal Adenocarcinoma Recruiting CRDF

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Borderline Resectable Pancreatic Ductal AdenocarcinomaLocally Advanced Pancreatic Ductal AdenocarcinomaMetastatic Pancreatic Ductal AdenocarcinomaOvarian CancerResectable Pancreatic Ductal AdenocarcinomaStage II Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8Unresectable Pancreatic Ductal AdenocarcinomaAcute Myeloid Leukemia (AML)Advanced Pancreatic AdenocarcinomaPancreatic CancerPancreatic Ductal Adenocarcinoma

Other drugs acting on WEE1

More from K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the ZNTL page.

Follow ZNTL, the company behind Azenosertib

See ZNTL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ZNTL catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.